SCHEMBL13536239

SCHEMBL13536239

CC1(C)OB(c2cncc(OCc3ccccc3)c2)OC1(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.60
LIPG Q9Y5X9 4/20 0.41
LPL P06858 3/20 0.41
PDGFRB P09619 2/20 0.40
PDGFRA P16234 1/20 0.40
MAOB P27338 3/20 0.39
MAPK1 P28482 2/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
CHRNB2 P17787 2/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CHRNA7 P36544 2/20 0.38
CHRNA4 P43681 2/20 0.38
ALOX5 P09917 1/20 0.38
KDR P35968 1/20 0.37
ACHE P22303 1/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240669 1.00 DGAT1 (0.60) DGAT1LIPGLPLPDGFRBPDGFRA
SCHEMBL12537365 0.90 DGAT1 (0.49) DGAT1PDGFRBPDGFRAMAOBMAPK1
SCHEMBL189898 0.87 DGAT1 (0.49) DGAT1LIPGLPLMAOB
SCHEMBL3619300 0.82 DGAT1 (0.57) DGAT1LIPGLPLMAOBALOX5
SCHEMBL298401 0.80 DGAT1 (0.72) DGAT1LIPGLPLMAOBMMP2
SCHEMBL2066788 0.80 AAK1 (0.39) DGAT1LIPGLPLCHRNB2CHRNB4
SCHEMBL30345297 0.79 DGAT1 (0.54) DGAT1LIPGLPLMAOBMMP2
SCHEMBL15554329 0.79 DGAT1 (0.54) DGAT1LIPGLPLMAOBMMP2
SCHEMBL16337257 0.79 DGAT1 (0.54) DGAT1LIPGLPLMAOBMMP2
SCHEMBL23496938 0.78 DGAT1 (0.56) DGAT1LIPGLPLPDGFRBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
US-11058676-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-13 US disclosed
EP-3414229-B1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-06-16 EP disclosed
US-10588900-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2020-03-17 US disclosed
US-20190046520-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2019-02-14 US disclosed
EP-3414229-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2018-12-19 EP disclosed
WO-2017139274-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-08-17 WO disclosed
WO-2010005558-A2 PI3K ISOFORM SELECTIVE INHIBITORS XCOVERY, INC. (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11058676-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX DGAT1 1577/4885LIPG 59/4885LPL 30/4885
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA DGAT1 2443/4885LIPG 2475/4885LPL 4524/4885
US-20190046520-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX DGAT1 1577/4885LIPG 59/4885LPL 30/4885
US-10588900-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX DGAT1 1577/4885LIPG 59/4885LPL 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.